ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global and India Beta-lactam and Beta-lactamase Inhibitors Market Report & Forecast 2023-2029
Published Date: December 2023
|
Report Code: QYRE-Auto-11T16331
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global and India Beta lactam and Beta lactamase Inhibitors Market Report Forecast 2023 2029
BUY CHAPTERS

Global and India Beta-lactam and Beta-lactamase Inhibitors Market Report & Forecast 2023-2029

Code: QYRE-Auto-11T16331
Report
December 2023
Pages:116
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Pfizer Inc
Novartis (Sandoz)
TEVA
Merck
AbbVie(Allergan)
Sumitomo Dainippon
Hikma
Aurobindo Pharma
WOCKHARDT
Lupin Ltd
Fresenius Kabi
B. Braun
USantibiotics
Qilu Pharmaceutical
ACS Dobfar
Nichi-Iko (Sagent)
Antibiotice

and India Beta-lactam and Beta-lactamase Inhibitors Market Size

The global Beta-lactam and Beta-lactamase Inhibitors revenue was US$ 28330 million in 2022 and is forecast to a readjusted size of US$ 32370 million by 2029 with a CAGR of 1.9% during the forecast period (2023-2029).

and India Beta-lactam and Beta-lactamase Inhibitors Market

and India Beta-lactam and Beta-lactamase Inhibitors Market

β-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related β-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of b-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to β-lactams is primarily because of bacterially produced β-lactamase enzymes that hydrolyze the β-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum β-lactamase inhibitors that work against many problematic β-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options.
In India, the Beta-lactam and Beta-lactamase Inhibitors revenue is expected to grow from US$ million in 2022 to US$ million by 2029, at a CAGR of % during the forecast period (2023-2029).
In the global market, the core manufacturers of Beta-lactam and Beta-lactamase Inhibitors include Pfizer and Novartis (Sandoz) etc, and the top 2 manufacturers account for about 10% of the market share. The market include Asia Pacific, Europe and North America, with a share of 33%, 32% and 28%. cephalosporins accounted for 28% and penicillins accounted for 17%. The product is mainly used in intravenous and oral, with a share of 65% and 35%.
This report focuses on global and India Beta-lactam and Beta-lactamase Inhibitors market, also covers the segmentation data of other regions in regional level and county level.
India is now the world’s most populous country. According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2023, powered by domestic investment. First and foremost, the key factor in India's rapid economic growth is the huge supply and demand from a large population base. Demand and supply sides working in both directions to support India's economic stability.
India is a market full of opportunities, and the demand for Beta-lactam and Beta-lactamase Inhibitors will continue to grow rapidly in the future.
Global Beta-lactam and Beta-lactamase Inhibitors Scope and Market Size
Beta-lactam and Beta-lactamase Inhibitors market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Beta-lactam and Beta-lactamase Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2029.
For India market, this report focuses on the Beta-lactam and Beta-lactamase Inhibitors market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in India.

Scope of and India Beta-lactam and Beta-lactamase Inhibitors Market Report

Report Metric Details
Report Name and India Beta-lactam and Beta-lactamase Inhibitors Market
Forecasted market size in 2029 US$ 32370 million
CAGR 1.9%
Forecasted years 2023 - 2029
Segment by Type
  • Penicillins
  • Cephalosporins
  • Carbapenems
  • Monobactams
  • Combinations
Segment by Application
  • Oral
  • Intravenous
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Pfizer, Novartis (Sandoz), TEVA, Merck, AbbVie (Allergan), Sumitomo Dainippon, Hikma, Aurobindo Pharma, Wockhardt, Lupin Limited, Fresenius Kabi, B. Braun, USantibiotics, Qilu Pharmaceutical, ACS Dobfar, Nichi-Iko (Sagent), Antibiotice
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

FAQ for this report

What is the and India Beta-lactam and Beta-lactamase Inhibitors Market size in 2029?

Ans: The and India Beta-lactam and Beta-lactamase Inhibitors Market size in 2029 will be US$ 32370 million.

What is the market share of major companies in and India Beta-lactam and Beta-lactamase Inhibitors Market?

Ans: In the global market, the core manufacturers of Beta-lactam and Beta-lactamase Inhibitors include Pfizer and Novartis (Sandoz) etc, and the top 2 manufacturers account for about 10% of the market share.

What is the and India Beta-lactam and Beta-lactamase Inhibitors Market share by type?

Ans: cephalosporins accounted for 28% and penicillins accounted for 17%.

What is the and India Beta-lactam and Beta-lactamase Inhibitors Market share by application?

Ans: The product is mainly used in intravenous and oral, with a share of 65% and 35%.

What is the and India Beta-lactam and Beta-lactamase Inhibitors Market share by region?

Ans: According to IMF (its July update to its World Economic Outlook), India’s GDP growth is projected at 6.1% in 2023, powered by domestic investment.

Who are the main players in the and India Beta-lactam and Beta-lactamase Inhibitors Market report?

Ans: The main players in the and India Beta-lactam and Beta-lactamase Inhibitors Market are Pfizer, Novartis (Sandoz), TEVA, Merck, AbbVie (Allergan), Sumitomo Dainippon, Hikma, Aurobindo Pharma, Wockhardt, Lupin Limited, Fresenius Kabi, B. Braun, USantibiotics, Qilu Pharmaceutical, ACS Dobfar, Nichi-Iko (Sagent), Antibiotice

What are the Application segmentation covered in the and India Beta-lactam and Beta-lactamase Inhibitors Market report?

Ans: The Applications covered in the and India Beta-lactam and Beta-lactamase Inhibitors Market report are Oral, Intravenous

What are the Type segmentation covered in the and India Beta-lactam and Beta-lactamase Inhibitors Market report?

Ans: The Types covered in the and India Beta-lactam and Beta-lactamase Inhibitors Market report are Penicillins, Cephalosporins, Carbapenems, Monobactams, Combinations

1 Study Coverage
1.1 Beta-lactam and Beta-lactamase Inhibitors Product Introduction
1.2 Global Beta-lactam and Beta-lactamase Inhibitors Outlook 2018 VS 2022 VS 2029
1.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales in US$ Million for the Year 2018-2029
1.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume for the Year 2018-2029
1.3 India Beta-lactam and Beta-lactamase Inhibitors Outlook 2018 VS 2022 VS 2029
1.3.1 India Beta-lactam and Beta-lactamase Inhibitors Sales in US$ Million for the Year 2018-2029
1.3.2 India Beta-lactam and Beta-lactamase Inhibitors Sales in Volume for the Year 2018-2029
1.4 Beta-lactam and Beta-lactamase Inhibitors Market Size, India VS Global, 2018 VS 2022 VS 2029
1.4.1 The Market Share of India Beta-lactam and Beta-lactamase Inhibitors in Global, 2018 VS 2022 VS 2029
1.4.2 The Growth Rate of Beta-lactam and Beta-lactamase Inhibitors Market Size, India VS Global, 2018 VS 2022 VS 2029
1.5 Beta-lactam and Beta-lactamase Inhibitors Market Dynamics
1.5.1 Beta-lactam and Beta-lactamase Inhibitors Industry Trends
1.5.2 Beta-lactam and Beta-lactamase Inhibitors Market Drivers
1.5.3 Beta-lactam and Beta-lactamase Inhibitors Market Challenges
1.5.4 Beta-lactam and Beta-lactamase Inhibitors Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Years Considered
2 Beta-lactam and Beta-lactamase Inhibitors by Type
2.1 Beta-lactam and Beta-lactamase Inhibitors Market Segment by Type
2.1.1 Penicillins
2.1.2 Cephalosporins
2.1.3 Carbapenems
2.1.4 Monobactams
2.1.5 Combinations
2.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
2.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value, by Type (2018, 2022 & 2029)
2.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Type (2018, 2022 & 2029)
2.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Average Selling Price (ASP) by Type (2018, 2022 & 2029)
2.3 India Beta-lactam and Beta-lactamase Inhibitors Market Size by Type
2.3.1 India Beta-lactam and Beta-lactamase Inhibitors Sales in Value, by Type (2018, 2022 & 2029)
2.3.2 India Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Type (2018, 2022 & 2029)
2.3.3 India Beta-lactam and Beta-lactamase Inhibitors Average Selling Price (ASP) by Type (2018, 2022 & 2029)
3 Beta-lactam and Beta-lactamase Inhibitors by Application
3.1 Beta-lactam and Beta-lactamase Inhibitors Market Segment by Application
3.1.1 Oral
3.1.2 Intravenous
3.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Application
3.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value, by Application (2018, 2022 & 2029)
3.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Application (2018, 2022 & 2029)
3.3.3 Global Beta-lactam and Beta-lactamase Inhibitors Average Selling Price (ASP) by Application (2018, 2022 & 2029)
3.3 India Beta-lactam and Beta-lactamase Inhibitors Market Size by Application
3.3.1 India Beta-lactam and Beta-lactamase Inhibitors Sales in Value, by Application (2018, 2022 & 2029)
3.3.2 India Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Application (2018, 2022 & 2029)
3.3.3 India Beta-lactam and Beta-lactamase Inhibitors Average Selling Price (ASP) by Application (2018, 2022 & 2029)
4 Global Beta-lactam and Beta-lactamase Inhibitors Competitor Landscape by Company
4.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Company
4.1.1 Global Key Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Ranked by Revenue (2022)
4.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturer (2018-2023)
4.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturer (2018-2023)
4.1.4 Global Beta-lactam and Beta-lactamase Inhibitors Price by Manufacturer (2018-2023)
4.2 Global Beta-lactam and Beta-lactamase Inhibitors Concentration Ratio (CR)
4.2.1 Beta-lactam and Beta-lactamase Inhibitors Market Concentration Ratio (CR)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Beta-lactam and Beta-lactamase Inhibitors in 2022
4.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Manufacturing Base Distribution and Headquarters
4.4 Global Key Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Product Offered and Application
4.5 Global Key Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Date of Enter into This Industry
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4.7 India Beta-lactam and Beta-lactamase Inhibitors Market Size by Company
4.7.1 Key Players of Beta-lactam and Beta-lactamase Inhibitors in India, Ranked by Revenue (2022)
4.7.2 India Beta-lactam and Beta-lactamase Inhibitors Revenue by Players (2018-2023)
4.7.3 India Beta-lactam and Beta-lactamase Inhibitors Sales by Players (2018-2023)
5 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Region
5.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size by Region: 2018 VS 2022 VS 2029
5.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Size in Volume by Region (2018-2029)
5.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Region: 2018-2023
5.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume Forecast by Region (2024-2029)
5.3 Global Beta-lactam and Beta-lactamase Inhibitors Market Size in Value by Region (2018-2029)
5.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Region: 2018-2023
5.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Region: 2024-2029
6 Americas
6.1 Americas Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2018-2029
6.2 Americas Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Type (2018, 2022 & 2029)
6.3 Americas Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Application (2018, 2022 & 2029)
6.4 Americas Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country (2018, 2022 & 2029)
6.4.1 Americas Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Country (2018, 2022 & 2029)
6.4.2 Americas Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Country (2018, 2022 & 2029)
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
6.4.6 Brazil
7 EMEA
7.1 EMEA Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2018-2029
7.2 EMEA Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Type (2018, 2022 & 2029)
7.3 EMEA Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Application (2018, 2022 & 2029)
7.4 EMEA Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Country (2018, 2022 & 2029)
7.4.1 EMEA Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Country (2018, 2022 & 2029)
7.4.2 EMEA Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Country (2018, 2022 & 2029)
7.4.3 Europe
7.4.4 Middle East
7.4.5 Africa
8 China
8.1 China Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2018-2029
8.2 China Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Type (2018, 2022 & 2029)
8.3 China Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Application (2018, 2022 & 2029)
9 APAC
9.1 APAC Beta-lactam and Beta-lactamase Inhibitors Market Size YoY Growth 2018-2029
9.2 APAC Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Type (2018, 2022 & 2029)
9.3 APAC Beta-lactam and Beta-lactamase Inhibitors Sales in Volume, by Application (2018, 2022 & 2029)
9.4 APAC Beta-lactam and Beta-lactamase Inhibitors Market Facts & Figures by Region (2018, 2022 & 2029)
9.4.1 APAC Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Region (2018, 2022 & 2029)
9.4.2 APAC Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Region (2018, 2022 & 2029)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Description and Business Overview
10.1.3 Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pfizer Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.1.5 Pfizer Recent Development
10.2 Novartis (Sandoz)
10.2.1 Novartis (Sandoz) Company Information
10.2.2 Novartis (Sandoz) Description and Business Overview
10.2.3 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.2.5 Novartis (Sandoz) Recent Development
10.3 TEVA
10.3.1 TEVA Company Information
10.3.2 TEVA Description and Business Overview
10.3.3 TEVA Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.3.4 TEVA Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.3.5 TEVA Recent Development
10.4 Merck
10.4.1 Merck Company Information
10.4.2 Merck Description and Business Overview
10.4.3 Merck Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Merck Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.4.5 Merck Recent Development
10.5 AbbVie (Allergan)
10.5.1 AbbVie (Allergan) Company Information
10.5.2 AbbVie (Allergan) Description and Business Overview
10.5.3 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.5.4 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.5.5 AbbVie (Allergan) Recent Development
10.6 Sumitomo Dainippon
10.6.1 Sumitomo Dainippon Company Information
10.6.2 Sumitomo Dainippon Description and Business Overview
10.6.3 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.6.5 Sumitomo Dainippon Recent Development
10.7 Hikma
10.7.1 Hikma Company Information
10.7.2 Hikma Description and Business Overview
10.7.3 Hikma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Hikma Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.7.5 Hikma Recent Development
10.8 Aurobindo Pharma
10.8.1 Aurobindo Pharma Company Information
10.8.2 Aurobindo Pharma Description and Business Overview
10.8.3 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.8.5 Aurobindo Pharma Recent Development
10.9 Wockhardt
10.9.1 Wockhardt Company Information
10.9.2 Wockhardt Description and Business Overview
10.9.3 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.9.5 Wockhardt Recent Development
10.10 Lupin Limited
10.10.1 Lupin Limited Company Information
10.10.2 Lupin Limited Description and Business Overview
10.10.3 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.10.5 Lupin Limited Recent Development
10.11 Fresenius Kabi
10.11.1 Fresenius Kabi Company Information
10.11.2 Fresenius Kabi Description and Business Overview
10.11.3 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.11.5 Fresenius Kabi Recent Development
10.12 B. Braun
10.12.1 B. Braun Company Information
10.12.2 B. Braun Description and Business Overview
10.12.3 B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.12.4 B. Braun Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.12.5 B. Braun Recent Development
10.13 USantibiotics
10.13.1 USantibiotics Company Information
10.13.2 USantibiotics Description and Business Overview
10.13.3 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.13.4 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.13.5 USantibiotics Recent Development
10.14 Qilu Pharmaceutical
10.14.1 Qilu Pharmaceutical Company Information
10.14.2 Qilu Pharmaceutical Description and Business Overview
10.14.3 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.14.5 Qilu Pharmaceutical Recent Development
10.15 ACS Dobfar
10.15.1 ACS Dobfar Company Information
10.15.2 ACS Dobfar Description and Business Overview
10.15.3 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.15.4 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.15.5 ACS Dobfar Recent Development
10.16 Nichi-Iko (Sagent)
10.16.1 Nichi-Iko (Sagent) Company Information
10.16.2 Nichi-Iko (Sagent) Description and Business Overview
10.16.3 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.16.5 Nichi-Iko (Sagent) Recent Development
10.17 Antibiotice
10.17.1 Antibiotice Company Information
10.17.2 Antibiotice Description and Business Overview
10.17.3 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.17.4 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Products Offered
10.17.5 Antibiotice Recent Development
11 Industry Chain and Sales Channels Analysis
11.1 Beta-lactam and Beta-lactamase Inhibitors Industry Chain Analysis
11.2 Beta-lactam and Beta-lactamase Inhibitors Key Raw Materials
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.3 Beta-lactam and Beta-lactamase Inhibitors Production Mode & Process
11.4 Beta-lactam and Beta-lactamase Inhibitors Sales and Marketing
11.4.1 Beta-lactam and Beta-lactamase Inhibitors Sales Channels
11.4.2 Beta-lactam and Beta-lactamase Inhibitors Distributors
11.5 Beta-lactam and Beta-lactamase Inhibitors Customers
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Pfizer Inc
Novartis (Sandoz)
TEVA
Merck
AbbVie(Allergan)
Sumitomo Dainippon
Hikma
Aurobindo Pharma
WOCKHARDT
Lupin Ltd
Fresenius Kabi
B. Braun
USantibiotics
Qilu Pharmaceutical
ACS Dobfar
Nichi-Iko (Sagent)
Antibiotice
List of Tables
    Table 1. Beta-lactam and Beta-lactamase Inhibitors CAGR in Value, India VS Global, 2018 VS 2022 VS 2029
    Table 2. Beta-lactam and Beta-lactamase Inhibitors Market Trends
    Table 3. Beta-lactam and Beta-lactamase Inhibitors Market Drivers
    Table 4. Beta-lactam and Beta-lactamase Inhibitors Market Challenges
    Table 5. Beta-lactam and Beta-lactamase Inhibitors Market Restraints
    Table 6. Global Beta-lactam and Beta-lactamase Inhibitors Sales Growth Rate (CAGR) by Type: 2018 VS 2022 VS 2029 (US$ Million)
    Table 7. India Beta-lactam and Beta-lactamase Inhibitors Sales Growth Rate (CAGR) by Type: 2018 VS 2022 VS 2029 (US$ Million)
    Table 8. Global Beta-lactam and Beta-lactamase Inhibitors Sales Growth Rate (CAGR) by Application: 2018 VS 2022 VS 2029 (US$ Million)
    Table 9. India Beta-lactam and Beta-lactamase Inhibitors Sales Growth Rate (CAGR) by Application: 2018 VS 2022 VS 2029 (US$ Million)
    Table 10. Global Key Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Ranked by Revenue (2022) & (US$ Million)
    Table 11. Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturer, (US$ Million), 2018-2023
    Table 12. Global Beta-lactam and Beta-lactamase Inhibitors Revenue Share by Manufacturer, 2018-2023
    Table 13. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturer, (M Units), 2018-2023
    Table 14. Global Beta-lactam and Beta-lactamase Inhibitors Sales Share by Manufacturer, 2018-2023
    Table 15. Global Beta-lactam and Beta-lactamase Inhibitors Price by Manufacturer (2018-2023) & (US$/Unit)
    Table 16. Global Beta-lactam and Beta-lactamase Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Beta-lactam and Beta-lactamase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Beta-lactam and Beta-lactamase Inhibitors as of 2022)
    Table 18. Global Key Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Manufacturing Base Distribution and Headquarters
    Table 19. Global Key Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Product Offered and Application
    Table 20. Global Key Manufacturers of Beta-lactam and Beta-lactamase Inhibitors, Date of Enter into This Industry
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Key Players of Beta-lactam and Beta-lactamase Inhibitors in India, Ranked by Revenue (2022) & (US$ million)
    Table 23. India Beta-lactam and Beta-lactamase Inhibitors Revenue by Players, (US$ Million), (2018-2023)
    Table 24. India Beta-lactam and Beta-lactamase Inhibitors Revenue Share by Players, (2018-2023)
    Table 25. India Beta-lactam and Beta-lactamase Inhibitors Sales by Players, (M Units), (2018-2023)
    Table 26. India Beta-lactam and Beta-lactamase Inhibitors Sales Share by Players, (2018-2023)
    Table 27. Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 28. Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Region (2018-2023) & (M Units)
    Table 29. Global Beta-lactam and Beta-lactamase Inhibitors Sales in Volume Forecast by Region (2024-2029) & (M Units)
    Table 30. Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Region (2018-2023) & (US$ Million)
    Table 31. Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value Forecast by Region (2024-2029) & (US$ Million)
    Table 32. Americas Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 33. Americas Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Country (2018-2023) & (US$ Million)
    Table 34. Americas Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Country (2024-2029) & (US$ Million)
    Table 35. Americas Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Country (2018-2023) & (M Units)
    Table 36. Americas Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Country (2024-2029) & (M Units)
    Table 37. EMEA Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 38. EMEA Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Country (2018-2023) & (US$ Million)
    Table 39. EMEA Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Country (2024-2029) & (US$ Million)
    Table 40. EMEA Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Country (2018-2023) & (M Units)
    Table 41. EMEA Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Country (2024-2029) & (M Units)
    Table 42. APAC Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 43. APAC Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Country (2018-2023) & (US$ Million)
    Table 44. APAC Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Country (2024-2029) & (US$ Million)
    Table 45. APAC Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Country (2018-2023) & (M Units)
    Table 46. APAC Beta-lactam and Beta-lactamase Inhibitors Sales in Volume by Country (2024-2029) & (M Units)
    Table 47. Pfizer Company Information
    Table 48. Pfizer Description and Business Overview
    Table 49. Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 50. Pfizer Beta-lactam and Beta-lactamase Inhibitors Product
    Table 51. Pfizer Recent Development
    Table 52. Novartis (Sandoz) Company Information
    Table 53. Novartis (Sandoz) Description and Business Overview
    Table 54. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 55. Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Product
    Table 56. Novartis (Sandoz) Recent Development
    Table 57. TEVA Company Information
    Table 58. TEVA Description and Business Overview
    Table 59. TEVA Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 60. TEVA Beta-lactam and Beta-lactamase Inhibitors Product
    Table 61. TEVA Recent Development
    Table 62. Merck Company Information
    Table 63. Merck Description and Business Overview
    Table 64. Merck Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 65. Merck Beta-lactam and Beta-lactamase Inhibitors Product
    Table 66. Merck Recent Development
    Table 67. AbbVie (Allergan) Company Information
    Table 68. AbbVie (Allergan) Description and Business Overview
    Table 69. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 70. AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Product
    Table 71. AbbVie (Allergan) Recent Development
    Table 72. Sumitomo Dainippon Company Information
    Table 73. Sumitomo Dainippon Description and Business Overview
    Table 74. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 75. Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Product
    Table 76. Sumitomo Dainippon Recent Development
    Table 77. Hikma Company Information
    Table 78. Hikma Description and Business Overview
    Table 79. Hikma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 80. Hikma Beta-lactam and Beta-lactamase Inhibitors Product
    Table 81. Hikma Recent Development
    Table 82. Aurobindo Pharma Company Information
    Table 83. Aurobindo Pharma Description and Business Overview
    Table 84. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 85. Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Product
    Table 86. Aurobindo Pharma Recent Development
    Table 87. Wockhardt Company Information
    Table 88. Wockhardt Description and Business Overview
    Table 89. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 90. Wockhardt Beta-lactam and Beta-lactamase Inhibitors Product
    Table 91. Wockhardt Recent Development
    Table 92. Lupin Limited Company Information
    Table 93. Lupin Limited Description and Business Overview
    Table 94. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 95. Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Product
    Table 96. Lupin Limited Recent Development
    Table 97. Fresenius Kabi Company Information
    Table 98. Fresenius Kabi Description and Business Overview
    Table 99. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 100. Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Product
    Table 101. Fresenius Kabi Recent Development
    Table 102. B. Braun Company Information
    Table 103. B. Braun Description and Business Overview
    Table 104. B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 105. B. Braun Beta-lactam and Beta-lactamase Inhibitors Product
    Table 106. B. Braun Recent Development
    Table 107. USantibiotics Company Information
    Table 108. USantibiotics Description and Business Overview
    Table 109. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 110. USantibiotics Beta-lactam and Beta-lactamase Inhibitors Product
    Table 111. USantibiotics Recent Development
    Table 112. Qilu Pharmaceutical Company Information
    Table 113. Qilu Pharmaceutical Description and Business Overview
    Table 114. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 115. Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Product
    Table 116. Qilu Pharmaceutical Recent Development
    Table 117. ACS Dobfar Company Information
    Table 118. ACS Dobfar Description and Business Overview
    Table 119. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 120. ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Product
    Table 121. ACS Dobfar Recent Development
    Table 122. Nichi-Iko (Sagent) Company Information
    Table 123. Nichi-Iko (Sagent) Description and Business Overview
    Table 124. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 125. Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Product
    Table 126. Nichi-Iko (Sagent) Recent Development
    Table 127. Antibiotice Company Information
    Table 128. Antibiotice Description and Business Overview
    Table 129. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
    Table 130. Antibiotice Beta-lactam and Beta-lactamase Inhibitors Product
    Table 131. Antibiotice Recent Development
    Table 132. Key Raw Materials Lists
    Table 133. Raw Materials Key Suppliers Lists
    Table 134. Beta-lactam and Beta-lactamase Inhibitors Customers List
    Table 135. Beta-lactam and Beta-lactamase Inhibitors Distributors List
    Table 136. Research Programs/Design for This Report
    Table 137. Key Data Information from Secondary Sources
    Table 138. Key Data Information from Primary Sources
List of Figures
    Figure 1. Beta-lactam and Beta-lactamase Inhibitors Product Picture
    Figure 2. Global Beta-lactam and Beta-lactamase Inhibitors Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 3. Global Beta-lactam and Beta-lactamase Inhibitors Market Size 2018-2029 (US$ Million)
    Figure 4. Global Beta-lactam and Beta-lactamase Inhibitors Sales 2018-2029 (M Units)
    Figure 5. India Beta-lactam and Beta-lactamase Inhibitors Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 6. India Beta-lactam and Beta-lactamase Inhibitors Market Size 2018-2029 (US$ Million)
    Figure 7. India Beta-lactam and Beta-lactamase Inhibitors Sales 2018-2029 (M Units)
    Figure 8. India Beta-lactam and Beta-lactamase Inhibitors Market Share in Global, in Value (US$ Million) 2018-2029
    Figure 9. India Beta-lactam and Beta-lactamase Inhibitors Market Share in Global, in Volume (M Units) 2018-2029
    Figure 10. Beta-lactam and Beta-lactamase Inhibitors Report Years Considered
    Figure 11. Product Picture of Penicillins
    Figure 12. Product Picture of Cephalosporins
    Figure 13. Product Picture of Carbapenems
    Figure 14. Product Picture of Monobactams
    Figure 15. Product Picture of Combinations
    Figure 16. Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Type in 2022 & 2029
    Figure 17. Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Type (2018-2029) & (US$ Million)
    Figure 18. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Type (2018-2029)
    Figure 19. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2018-2029) & (M Units)
    Figure 20. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type (2018-2029)
    Figure 21. Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2018-2029) & (US$/Unit)
    Figure 22. India Beta-lactam and Beta-lactamase Inhibitors Market Share by Type in 2022 & 2029
    Figure 23. India Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Type (2018-2029) & (US$ Million)
    Figure 24. India Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Type (2018-2029)
    Figure 25. India Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2018-2029) & (M Units)
    Figure 26. India Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type (2018-2029)
    Figure 27. India Beta-lactam and Beta-lactamase Inhibitors Price by Type (2018-2029) & (US$/Unit)
    Figure 28. Product Picture of Oral
    Figure 29. Product Picture of Intravenous
    Figure 30. Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Application in 2022 & 2029
    Figure 31. Global Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Application (2018-2029) & (US$ Million)
    Figure 32. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Application (2018-2029)
    Figure 33. Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2018-2029) & (M Units)
    Figure 34. Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application (2018-2029)
    Figure 35. Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2018-2029) & (US$/Unit)
    Figure 36. India Beta-lactam and Beta-lactamase Inhibitors Market Share by Application in 2022 & 2029
    Figure 37. India Beta-lactam and Beta-lactamase Inhibitors Sales in Value by Application (2018-2029) & (US$ Million)
    Figure 38. India Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Value by Application (2018-2029)
    Figure 39. India Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2018-2029) & (M Units)
    Figure 40. India Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application (2018-2029)
    Figure 41. India Beta-lactam and Beta-lactamase Inhibitors Price by Application (2018-2029) & (US$/Unit)
    Figure 42. Americas Beta-lactam and Beta-lactamase Inhibitors Sales in Volume Growth Rate 2018-2029 (M Units)
    Figure 43. Americas Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate 2018-2029 (US$ Million)
    Figure 44. Americas Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2018-2029) & (M Units)
    Figure 45. Americas Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type (2018-2029)
    Figure 46. Americas Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2018-2029) & (M Units)
    Figure 47. Americas Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application (2018-2029)
    Figure 48. United States Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2018-2029) & (US$ Million)
    Figure 49. Canada Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2018-2029) & (US$ Million)
    Figure 50. Mexico Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2018-2029) & (US$ Million)
    Figure 51. Brazil Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2018-2029) & (US$ Million)
    Figure 52. EMEA Beta-lactam and Beta-lactamase Inhibitors Sales in Volume Growth Rate 2018-2029 (M Units)
    Figure 53. EMEA Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate 2018-2029 (US$ Million)
    Figure 54. EMEA Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2018-2029) & (M Units)
    Figure 55. EMEA Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type (2018-2029)
    Figure 56. EMEA Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2018-2029) & (M Units)
    Figure 57. EMEA Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application (2018-2029)
    Figure 58. Europe Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2018-2029) & (US$ Million)
    Figure 59. Middle East Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2018-2029) & (US$ Million)
    Figure 60. Africa Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2018-2029) & (US$ Million)
    Figure 61. China Beta-lactam and Beta-lactamase Inhibitors Sales in Volume Growth Rate 2018-2029 (M Units)
    Figure 62. China Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate 2018-2029 (US$ Million)
    Figure 63. China Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2018-2029) & (M Units)
    Figure 64. China Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type (2018-2029)
    Figure 65. China Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2018-2029) & (M Units)
    Figure 66. China Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application (2018-2029)
    Figure 67. APAC Beta-lactam and Beta-lactamase Inhibitors Sales in Volume Growth Rate 2018-2029 (M Units)
    Figure 68. APAC Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate 2018-2029 (US$ Million)
    Figure 69. APAC Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2018-2029) & (M Units)
    Figure 70. APAC Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Type (2018-2029)
    Figure 71. APAC Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2018-2029) & (M Units)
    Figure 72. APAC Beta-lactam and Beta-lactamase Inhibitors Sales Market Share in Volume by Application (2018-2029)
    Figure 73. Japan Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2018-2029) & (US$ Million)
    Figure 74. South Korea Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2018-2029) & (US$ Million)
    Figure 75. China Taiwan Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2018-2029) & (US$ Million)
    Figure 76. Southeast Asia Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2018-2029) & (US$ Million)
    Figure 77. India Beta-lactam and Beta-lactamase Inhibitors Sales in Value Growth Rate (2018-2029) & (US$ Million)
    Figure 78. Beta-lactam and Beta-lactamase Inhibitors Value Chain
    Figure 79. Beta-lactam and Beta-lactamase Inhibitors Production Process
    Figure 80. Channels of Distribution
    Figure 81. Distributors Profiles
    Figure 82. Bottom-up and Top-down Approaches for This Report
    Figure 83. Data Triangulation
    Figure 84. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4350

This license allows only one user to access the PDF.
Electronic (PDF)

$6525

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$8700

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Feline Infectious Peritonitis (FIP) Antivirals Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-4U20267
Mon Nov 24 00:00:00 UTC 2025

Add to Cart

Global Anticoccidial Solutions Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-16R16865
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Bacterial Enteric Disease Testing Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-3F17301
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Whooping Cough Vaccination Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages
Type: Report
Code: QYRE-Auto-4B20221
Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions